The Potential Public Health Impact of New Immunization Strategies for the Prevention of RSV in Children in Panama
Author(s)
Saez-Llorens X1, Lasalvia P2, Jaramillo P2, DeAntonio R3
1Hospital del Niño Dr. José Renán Esquivel, Panamá, Panamá; Sistema Nacional de Investigación at Secretaria Nacional de Ciencia y Tecnologia (SENACYT), Panama, Panama, Panama, 2NeuroEconomix, Bogotá, CUN, Colombia, 3Cevaxin Centro de Vacunación e Investigación The Panama Clinic, Panamá, Panamá, Panama
Presentation Documents
OBJECTIVES: Respiratory syncytial virus (RSV) is a leading cause of morbimortality in children, affecting mostly healthy infants during their first year of life. In Panama, RSV circulates year-round, with most cases occurring between July and December. New strategies to reduce the burden of RSV disease have become available the direct protection of the babies using nirsevimab (long-acting monoclonal antibody) and through maternal immunization with the RSVpreF (bivalent RSV-prefusion-F-protein- This study compares the potential impact of the RSV preventive immunization strategies in Panama over one calendar year from a payer’s perspective.
METHODS: A static analytical decision-making model was used to evaluate the use of nirsevimab in the birth cohort of infant under 1 year of age, as well, as RSV maternal immunization from week 32 of pregnancy, Total number of RSV cases, emergency visits, hospitalizations (including ICU), outpatient visits, deaths, and associated costs prevented by Nirsevimab and RSVpreF were separately estimated and compared with the current standard of care corresponding to palivizumab in the high-risk population only. Efficacy and effectiveness estimates were obtained from the literature separately since there are no head-to-head trials. Additionally, the number needed to immunize was calculated for both strategies.
RESULTS: Nirsevimab would prevent more RSV cases overall (11,448 vs 5,140) than RSVpreF. including emergency visits (4,331 vs 1,639), hospitalizations (1,775 vs 870), ICU (109 vs 58). outpatient visits (5,233 vs 2,574) and deaths (15 vs 6).
Nirsevimab would save US$957,237 in associated costs. The NNI to prevent a RSV case and a RSV death with nirsevimab and RSVpreF would be 6 vs 10 and 4,138 vs 6,622, respectively.CONCLUSIONS: Nirsevimab is estimated to generate a larger public health impact as compared to RSV maternal immunization in Panama. This difference is mostly due to Nirsevimab sustained efficacy, timely immunization and ability to protect infants regardless of gestational age birth.
Conference/Value in Health Info
Value in Health, Volume 27, Issue 12, S2 (December 2024)
Code
EE488
Topic
Economic Evaluation, Epidemiology & Public Health
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis, Public Health
Disease
Pediatrics, Vaccines